nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—Plasma cell myeloma—Melphalan—ovarian cancer	0.0198	0.0896	CcSEcCtD
Ruxolitinib—Plasmacytoma—Melphalan—ovarian cancer	0.0198	0.0896	CcSEcCtD
Ruxolitinib—Myelosuppression—Altretamine—ovarian cancer	0.0157	0.0711	CcSEcCtD
Ruxolitinib—Myelosuppression—Topotecan—ovarian cancer	0.00496	0.0225	CcSEcCtD
Ruxolitinib—Myelosuppression—Melphalan—ovarian cancer	0.00485	0.022	CcSEcCtD
Ruxolitinib—Pancytopenia—Altretamine—ovarian cancer	0.00438	0.0199	CcSEcCtD
Ruxolitinib—Myelosuppression—Vinorelbine—ovarian cancer	0.00424	0.0192	CcSEcCtD
Ruxolitinib—ROCK1—Irinotecan—Topotecan—ovarian cancer	0.00392	0.371	CbGdCrCtD
Ruxolitinib—Anaemia—Altretamine—ovarian cancer	0.00297	0.0135	CcSEcCtD
Ruxolitinib—Myelosuppression—Paclitaxel—ovarian cancer	0.00285	0.0129	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Altretamine—ovarian cancer	0.00257	0.0116	CcSEcCtD
Ruxolitinib—Night sweats—Paclitaxel—ovarian cancer	0.00248	0.0112	CcSEcCtD
Ruxolitinib—Bone pain—Topotecan—ovarian cancer	0.00243	0.011	CcSEcCtD
Ruxolitinib—Myelosuppression—Docetaxel—ovarian cancer	0.00242	0.011	CcSEcCtD
Ruxolitinib—Fatigue—Altretamine—ovarian cancer	0.00226	0.0103	CcSEcCtD
Ruxolitinib—Asthenia—Altretamine—ovarian cancer	0.00188	0.00853	CcSEcCtD
Ruxolitinib—Infection—Carboplatin—ovarian cancer	0.0018	0.00816	CcSEcCtD
Ruxolitinib—Herpes zoster—Paclitaxel—ovarian cancer	0.00178	0.00806	CcSEcCtD
Ruxolitinib—Dizziness—Altretamine—ovarian cancer	0.00173	0.00786	CcSEcCtD
Ruxolitinib—PRKG2—testis—ovarian cancer	0.00169	0.00552	CbGeAlD
Ruxolitinib—CAMK1—gonad—ovarian cancer	0.00164	0.00536	CbGeAlD
Ruxolitinib—Myelosuppression—Epirubicin—ovarian cancer	0.00163	0.0074	CcSEcCtD
Ruxolitinib—JAK1—epithelium—ovarian cancer	0.00161	0.00529	CbGeAlD
Ruxolitinib—DCLK3—vagina—ovarian cancer	0.00161	0.00526	CbGeAlD
Ruxolitinib—JAK1—uterine cervix—ovarian cancer	0.0016	0.00524	CbGeAlD
Ruxolitinib—DCLK1—uterine cervix—ovarian cancer	0.0016	0.00524	CbGeAlD
Ruxolitinib—PLK1—Chlorambucil—Melphalan—ovarian cancer	0.0016	0.152	CbGdCrCtD
Ruxolitinib—PRKCE—testis—ovarian cancer	0.00157	0.00515	CbGeAlD
Ruxolitinib—PLK3—female reproductive system—ovarian cancer	0.00156	0.00512	CbGeAlD
Ruxolitinib—Pancytopenia—Chlorambucil—ovarian cancer	0.00156	0.00706	CcSEcCtD
Ruxolitinib—CAMK2G—myometrium—ovarian cancer	0.00154	0.00504	CbGeAlD
Ruxolitinib—Contusion—Paclitaxel—ovarian cancer	0.00153	0.00695	CcSEcCtD
Ruxolitinib—Neutropenia—Chlorambucil—ovarian cancer	0.00153	0.00695	CcSEcCtD
Ruxolitinib—DAPK2—uterine cervix—ovarian cancer	0.00153	0.005	CbGeAlD
Ruxolitinib—LRRK2—myometrium—ovarian cancer	0.00153	0.005	CbGeAlD
Ruxolitinib—JAK1—decidua—ovarian cancer	0.00153	0.00499	CbGeAlD
Ruxolitinib—RPS6KA6—testis—ovarian cancer	0.00151	0.00495	CbGeAlD
Ruxolitinib—PLK1—testis—ovarian cancer	0.00151	0.00495	CbGeAlD
Ruxolitinib—MAST1—testis—ovarian cancer	0.00151	0.00495	CbGeAlD
Ruxolitinib—LTK—female reproductive system—ovarian cancer	0.00151	0.00494	CbGeAlD
Ruxolitinib—Myelosuppression—Doxorubicin—ovarian cancer	0.00151	0.00684	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Topotecan—ovarian cancer	0.00149	0.00675	CcSEcCtD
Ruxolitinib—CAMK1—female reproductive system—ovarian cancer	0.00146	0.00479	CbGeAlD
Ruxolitinib—JAK1—endometrium—ovarian cancer	0.00145	0.00474	CbGeAlD
Ruxolitinib—DCLK3—testis—ovarian cancer	0.00143	0.00469	CbGeAlD
Ruxolitinib—Body temperature increased—Carboplatin—ovarian cancer	0.00143	0.00649	CcSEcCtD
Ruxolitinib—PLK3—female gonad—ovarian cancer	0.00142	0.00466	CbGeAlD
Ruxolitinib—CLK2—uterine cervix—ovarian cancer	0.00142	0.00466	CbGeAlD
Ruxolitinib—MARK2—female reproductive system—ovarian cancer	0.00142	0.00465	CbGeAlD
Ruxolitinib—PLK3—vagina—ovarian cancer	0.00141	0.00463	CbGeAlD
Ruxolitinib—Bone pain—Paclitaxel—ovarian cancer	0.0014	0.00633	CcSEcCtD
Ruxolitinib—ROCK1—epithelium—ovarian cancer	0.00139	0.00455	CbGeAlD
Ruxolitinib—Pancytopenia—Topotecan—ovarian cancer	0.00139	0.00628	CcSEcCtD
Ruxolitinib—MAP3K7—myometrium—ovarian cancer	0.00139	0.00453	CbGeAlD
Ruxolitinib—DAPK2—endometrium—ovarian cancer	0.00138	0.00452	CbGeAlD
Ruxolitinib—DAPK3—decidua—ovarian cancer	0.00137	0.00448	CbGeAlD
Ruxolitinib—Neutropenia—Topotecan—ovarian cancer	0.00136	0.00619	CcSEcCtD
Ruxolitinib—TYK2—myometrium—ovarian cancer	0.00136	0.00445	CbGeAlD
Ruxolitinib—Pancytopenia—Melphalan—ovarian cancer	0.00136	0.00615	CcSEcCtD
Ruxolitinib—CLK2—decidua—ovarian cancer	0.00136	0.00444	CbGeAlD
Ruxolitinib—JAK1—gonad—ovarian cancer	0.00134	0.0044	CbGeAlD
Ruxolitinib—MKNK2—myometrium—ovarian cancer	0.00134	0.00439	CbGeAlD
Ruxolitinib—Neutropenia—Melphalan—ovarian cancer	0.00134	0.00606	CcSEcCtD
Ruxolitinib—PLK4—gonad—ovarian cancer	0.00133	0.00437	CbGeAlD
Ruxolitinib—JAK1—uterus—ovarian cancer	0.00133	0.00437	CbGeAlD
Ruxolitinib—DCLK1—uterus—ovarian cancer	0.00133	0.00437	CbGeAlD
Ruxolitinib—CAMK1—female gonad—ovarian cancer	0.00133	0.00436	CbGeAlD
Ruxolitinib—Weight increased—Topotecan—ovarian cancer	0.00133	0.00602	CcSEcCtD
Ruxolitinib—CAMK1—vagina—ovarian cancer	0.00132	0.00433	CbGeAlD
Ruxolitinib—PHKG2—gonad—ovarian cancer	0.0013	0.00427	CbGeAlD
Ruxolitinib—Infestation NOS—Topotecan—ovarian cancer	0.0013	0.0059	CcSEcCtD
Ruxolitinib—Infestation—Topotecan—ovarian cancer	0.0013	0.0059	CcSEcCtD
Ruxolitinib—DAPK3—endometrium—ovarian cancer	0.0013	0.00425	CbGeAlD
Ruxolitinib—CLK2—endometrium—ovarian cancer	0.00129	0.00421	CbGeAlD
Ruxolitinib—DYRK1A—decidua—ovarian cancer	0.00128	0.00419	CbGeAlD
Ruxolitinib—NUAK2—uterine cervix—ovarian cancer	0.00128	0.00419	CbGeAlD
Ruxolitinib—BMPR2—decidua—ovarian cancer	0.00128	0.00418	CbGeAlD
Ruxolitinib—PLK3—testis—ovarian cancer	0.00126	0.00413	CbGeAlD
Ruxolitinib—RET—embryo—ovarian cancer	0.00126	0.00412	CbGeAlD
Ruxolitinib—HIPK2—gonad—ovarian cancer	0.00125	0.0041	CbGeAlD
Ruxolitinib—JAK2—myometrium—ovarian cancer	0.00124	0.00405	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Topotecan—ovarian cancer	0.00123	0.00558	CcSEcCtD
Ruxolitinib—Epistaxis—Topotecan—ovarian cancer	0.00123	0.00556	CcSEcCtD
Ruxolitinib—NUAK2—decidua—ovarian cancer	0.00122	0.00399	CbGeAlD
Ruxolitinib—LTK—testis—ovarian cancer	0.00122	0.00399	CbGeAlD
Ruxolitinib—JAK3—female reproductive system—ovarian cancer	0.00121	0.00395	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Melphalan—ovarian cancer	0.0012	0.00546	CcSEcCtD
Ruxolitinib—JAK1—female reproductive system—ovarian cancer	0.0012	0.00393	CbGeAlD
Ruxolitinib—CAMK2G—uterine cervix—ovarian cancer	0.0012	0.00392	CbGeAlD
Ruxolitinib—BMP2K—uterine cervix—ovarian cancer	0.0012	0.00392	CbGeAlD
Ruxolitinib—DAPK3—uterus—ovarian cancer	0.0012	0.00392	CbGeAlD
Ruxolitinib—TAOK2—female gonad—ovarian cancer	0.0012	0.00391	CbGeAlD
Ruxolitinib—CLK2—gonad—ovarian cancer	0.00119	0.00391	CbGeAlD
Ruxolitinib—MAP3K3—myometrium—ovarian cancer	0.00119	0.0039	CbGeAlD
Ruxolitinib—PLK4—female reproductive system—ovarian cancer	0.00119	0.0039	CbGeAlD
Ruxolitinib—JAK2—embryo—ovarian cancer	0.00119	0.0039	CbGeAlD
Ruxolitinib—TAOK2—vagina—ovarian cancer	0.00119	0.00389	CbGeAlD
Ruxolitinib—LRRK2—uterine cervix—ovarian cancer	0.00119	0.00389	CbGeAlD
Ruxolitinib—Pancytopenia—Vinorelbine—ovarian cancer	0.00119	0.00537	CcSEcCtD
Ruxolitinib—Bone pain—Docetaxel—ovarian cancer	0.00118	0.00537	CcSEcCtD
Ruxolitinib—CAMK1—testis—ovarian cancer	0.00118	0.00386	CbGeAlD
Ruxolitinib—Haemoglobin—Topotecan—ovarian cancer	0.00117	0.00532	CcSEcCtD
Ruxolitinib—Haemorrhage—Topotecan—ovarian cancer	0.00117	0.00529	CcSEcCtD
Ruxolitinib—Neutropenia—Vinorelbine—ovarian cancer	0.00117	0.00529	CcSEcCtD
Ruxolitinib—PHKG2—female reproductive system—ovarian cancer	0.00116	0.00381	CbGeAlD
Ruxolitinib—NUAK2—endometrium—ovarian cancer	0.00116	0.00379	CbGeAlD
Ruxolitinib—ROCK1—gonad—ovarian cancer	0.00116	0.00379	CbGeAlD
Ruxolitinib—Haemoglobin—Melphalan—ovarian cancer	0.00115	0.00521	CcSEcCtD
Ruxolitinib—MARK2—testis—ovarian cancer	0.00115	0.00375	CbGeAlD
Ruxolitinib—Haemorrhage—Melphalan—ovarian cancer	0.00114	0.00518	CcSEcCtD
Ruxolitinib—BMP2K—decidua—ovarian cancer	0.00114	0.00374	CbGeAlD
Ruxolitinib—PRKCE—lymph node—ovarian cancer	0.00114	0.00373	CbGeAlD
Ruxolitinib—JAK1—bone marrow—ovarian cancer	0.00113	0.00371	CbGeAlD
Ruxolitinib—LRRK2—decidua—ovarian cancer	0.00113	0.0037	CbGeAlD
Ruxolitinib—Weight decreased—Vinorelbine—ovarian cancer	0.00113	0.00512	CcSEcCtD
Ruxolitinib—DYRK1A—gonad—ovarian cancer	0.00113	0.00369	CbGeAlD
Ruxolitinib—STK16—female reproductive system—ovarian cancer	0.00113	0.00368	CbGeAlD
Ruxolitinib—PLK4—bone marrow—ovarian cancer	0.00113	0.00368	CbGeAlD
Ruxolitinib—HIPK2—female reproductive system—ovarian cancer	0.00112	0.00367	CbGeAlD
Ruxolitinib—BMPR2—uterus—ovarian cancer	0.00112	0.00365	CbGeAlD
Ruxolitinib—Infestation—Vinorelbine—ovarian cancer	0.00111	0.00505	CcSEcCtD
Ruxolitinib—Infestation NOS—Vinorelbine—ovarian cancer	0.00111	0.00505	CcSEcCtD
Ruxolitinib—PLK1—Irinotecan—Topotecan—ovarian cancer	0.00111	0.105	CbGdCrCtD
Ruxolitinib—JAK3—female gonad—ovarian cancer	0.0011	0.0036	CbGeAlD
Ruxolitinib—MAP3K19—female reproductive system—ovarian cancer	0.0011	0.00359	CbGeAlD
Ruxolitinib—PLK1—lymph node—ovarian cancer	0.0011	0.00359	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—ovarian cancer	0.0011	0.00359	CbGeAlD
Ruxolitinib—JAK1—female gonad—ovarian cancer	0.00109	0.00357	CbGeAlD
Ruxolitinib—MAP3K2—uterine cervix—ovarian cancer	0.00109	0.00356	CbGeAlD
Ruxolitinib—TAOK3—myometrium—ovarian cancer	0.00109	0.00356	CbGeAlD
Ruxolitinib—JAK1—vagina—ovarian cancer	0.00108	0.00355	CbGeAlD
Ruxolitinib—DCLK1—vagina—ovarian cancer	0.00108	0.00355	CbGeAlD
Ruxolitinib—CAMK2G—endometrium—ovarian cancer	0.00108	0.00355	CbGeAlD
Ruxolitinib—BMP2K—endometrium—ovarian cancer	0.00108	0.00355	CbGeAlD
Ruxolitinib—DAPK2—bone marrow—ovarian cancer	0.00108	0.00354	CbGeAlD
Ruxolitinib—MAP3K7—uterine cervix—ovarian cancer	0.00108	0.00353	CbGeAlD
Ruxolitinib—DAPK3—female reproductive system—ovarian cancer	0.00108	0.00352	CbGeAlD
Ruxolitinib—LRRK2—endometrium—ovarian cancer	0.00107	0.00352	CbGeAlD
Ruxolitinib—CLK2—female reproductive system—ovarian cancer	0.00107	0.00349	CbGeAlD
Ruxolitinib—CAMK1D—female gonad—ovarian cancer	0.00107	0.00349	CbGeAlD
Ruxolitinib—TAOK2—testis—ovarian cancer	0.00106	0.00347	CbGeAlD
Ruxolitinib—PHKG2—female gonad—ovarian cancer	0.00106	0.00347	CbGeAlD
Ruxolitinib—CAMK1D—vagina—ovarian cancer	0.00106	0.00347	CbGeAlD
Ruxolitinib—TYK2—uterine cervix—ovarian cancer	0.00106	0.00347	CbGeAlD
Ruxolitinib—Anaemia—Chlorambucil—ovarian cancer	0.00106	0.00479	CcSEcCtD
Ruxolitinib—MKNK2—epithelium—ovarian cancer	0.00105	0.00345	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Vinorelbine—ovarian cancer	0.00105	0.00477	CcSEcCtD
Ruxolitinib—IRAK1—uterine cervix—ovarian cancer	0.00104	0.00342	CbGeAlD
Ruxolitinib—MKNK2—uterine cervix—ovarian cancer	0.00104	0.00342	CbGeAlD
Ruxolitinib—DAPK2—female gonad—ovarian cancer	0.00104	0.00341	CbGeAlD
Ruxolitinib—DAPK2—vagina—ovarian cancer	0.00103	0.00339	CbGeAlD
Ruxolitinib—ROCK1—female reproductive system—ovarian cancer	0.00103	0.00338	CbGeAlD
Ruxolitinib—RET—epithelium—ovarian cancer	0.00103	0.00336	CbGeAlD
Ruxolitinib—MAP3K7—decidua—ovarian cancer	0.00103	0.00336	CbGeAlD
Ruxolitinib—STK16—female gonad—ovarian cancer	0.00102	0.00335	CbGeAlD
Ruxolitinib—HIPK2—female gonad—ovarian cancer	0.00102	0.00334	CbGeAlD
Ruxolitinib—STK16—vagina—ovarian cancer	0.00102	0.00333	CbGeAlD
Ruxolitinib—Malnutrition—Topotecan—ovarian cancer	0.00102	0.00461	CcSEcCtD
Ruxolitinib—Herpes zoster—Epirubicin—ovarian cancer	0.00102	0.00461	CcSEcCtD
Ruxolitinib—TYK2—decidua—ovarian cancer	0.00101	0.0033	CbGeAlD
Ruxolitinib—DYRK1A—female reproductive system—ovarian cancer	0.00101	0.0033	CbGeAlD
Ruxolitinib—CLK2—bone marrow—ovarian cancer	0.00101	0.00329	CbGeAlD
Ruxolitinib—BMP2K—gonad—ovarian cancer	0.00101	0.00329	CbGeAlD
Ruxolitinib—BMPR2—female reproductive system—ovarian cancer	0.001	0.00328	CbGeAlD
Ruxolitinib—CAMK2G—uterus—ovarian cancer	0.000999	0.00327	CbGeAlD
Ruxolitinib—LRRK2—gonad—ovarian cancer	0.000996	0.00326	CbGeAlD
Ruxolitinib—MKNK2—decidua—ovarian cancer	0.000995	0.00326	CbGeAlD
Ruxolitinib—IRAK1—decidua—ovarian cancer	0.000995	0.00326	CbGeAlD
Ruxolitinib—DAPK3—female gonad—ovarian cancer	0.000979	0.0032	CbGeAlD
Ruxolitinib—MAP3K7—endometrium—ovarian cancer	0.000975	0.00319	CbGeAlD
Ruxolitinib—JAK3—testis—ovarian cancer	0.000974	0.00319	CbGeAlD
Ruxolitinib—DAPK3—vagina—ovarian cancer	0.000973	0.00318	CbGeAlD
Ruxolitinib—JAK2—epithelium—ovarian cancer	0.000971	0.00318	CbGeAlD
Ruxolitinib—RET—decidua—ovarian cancer	0.000971	0.00318	CbGeAlD
Ruxolitinib—CLK2—female gonad—ovarian cancer	0.00097	0.00317	CbGeAlD
Ruxolitinib—JAK1—testis—ovarian cancer	0.000968	0.00317	CbGeAlD
Ruxolitinib—DCLK1—testis—ovarian cancer	0.000968	0.00317	CbGeAlD
Ruxolitinib—CLK2—vagina—ovarian cancer	0.000964	0.00316	CbGeAlD
Ruxolitinib—JAK2—uterine cervix—ovarian cancer	0.000963	0.00315	CbGeAlD
Ruxolitinib—PLK4—testis—ovarian cancer	0.000962	0.00315	CbGeAlD
Ruxolitinib—TYK2—endometrium—ovarian cancer	0.000957	0.00313	CbGeAlD
Ruxolitinib—MKNK2—endometrium—ovarian cancer	0.000945	0.00309	CbGeAlD
Ruxolitinib—CAMK1D—testis—ovarian cancer	0.000945	0.00309	CbGeAlD
Ruxolitinib—Herpes zoster—Doxorubicin—ovarian cancer	0.00094	0.00426	CcSEcCtD
Ruxolitinib—ROCK1—female gonad—ovarian cancer	0.00094	0.00308	CbGeAlD
Ruxolitinib—Anaemia—Topotecan—ovarian cancer	0.000939	0.00426	CcSEcCtD
Ruxolitinib—PHKG2—testis—ovarian cancer	0.000939	0.00307	CbGeAlD
Ruxolitinib—MAP3K3—uterine cervix—ovarian cancer	0.000928	0.00304	CbGeAlD
Ruxolitinib—Infection—Chlorambucil—ovarian cancer	0.000926	0.0042	CcSEcCtD
Ruxolitinib—DAPK2—testis—ovarian cancer	0.000923	0.00302	CbGeAlD
Ruxolitinib—Anaemia—Melphalan—ovarian cancer	0.00092	0.00417	CcSEcCtD
Ruxolitinib—JAK2—decidua—ovarian cancer	0.000917	0.003	CbGeAlD
Ruxolitinib—DYRK1A—female gonad—ovarian cancer	0.000917	0.003	CbGeAlD
Ruxolitinib—PLK3—lymph node—ovarian cancer	0.000914	0.00299	CbGeAlD
Ruxolitinib—BMPR2—female gonad—ovarian cancer	0.000913	0.00299	CbGeAlD
Ruxolitinib—MAP3K2—gonad—ovarian cancer	0.000913	0.00299	CbGeAlD
Ruxolitinib—Thrombocytopenia—Chlorambucil—ovarian cancer	0.000912	0.00414	CcSEcCtD
Ruxolitinib—STK16—testis—ovarian cancer	0.000908	0.00297	CbGeAlD
Ruxolitinib—BMPR2—vagina—ovarian cancer	0.000907	0.00297	CbGeAlD
Ruxolitinib—MAP3K2—uterus—ovarian cancer	0.000907	0.00297	CbGeAlD
Ruxolitinib—NUAK2—bone marrow—ovarian cancer	0.000905	0.00296	CbGeAlD
Ruxolitinib—HIPK2—testis—ovarian cancer	0.000904	0.00296	CbGeAlD
Ruxolitinib—MAP3K7—uterus—ovarian cancer	0.000898	0.00294	CbGeAlD
Ruxolitinib—CAMK2G—female reproductive system—ovarian cancer	0.000898	0.00294	CbGeAlD
Ruxolitinib—BMP2K—female reproductive system—ovarian cancer	0.000898	0.00294	CbGeAlD
Ruxolitinib—LRRK2—female reproductive system—ovarian cancer	0.00089	0.00291	CbGeAlD
Ruxolitinib—MAP3K19—testis—ovarian cancer	0.000885	0.0029	CbGeAlD
Ruxolitinib—MAP3K3—decidua—ovarian cancer	0.000884	0.00289	CbGeAlD
Ruxolitinib—LTK—lymph node—ovarian cancer	0.000883	0.00289	CbGeAlD
Ruxolitinib—TYK2—uterus—ovarian cancer	0.000882	0.00289	CbGeAlD
Ruxolitinib—MKNK2—gonad—ovarian cancer	0.000876	0.00287	CbGeAlD
Ruxolitinib—NUAK2—female gonad—ovarian cancer	0.000872	0.00286	CbGeAlD
Ruxolitinib—JAK2—endometrium—ovarian cancer	0.000871	0.00285	CbGeAlD
Ruxolitinib—MKNK2—uterus—ovarian cancer	0.000871	0.00285	CbGeAlD
Ruxolitinib—Malnutrition—Vinorelbine—ovarian cancer	0.000869	0.00394	CcSEcCtD
Ruxolitinib—DAPK3—testis—ovarian cancer	0.000868	0.00284	CbGeAlD
Ruxolitinib—NUAK2—vagina—ovarian cancer	0.000867	0.00284	CbGeAlD
Ruxolitinib—CLK2—testis—ovarian cancer	0.00086	0.00282	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.000859	0.0039	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Paclitaxel—ovarian cancer	0.000856	0.00388	CcSEcCtD
Ruxolitinib—CAMK1—lymph node—ovarian cancer	0.000855	0.0028	CbGeAlD
Ruxolitinib—BMP2K—bone marrow—ovarian cancer	0.000848	0.00277	CbGeAlD
Ruxolitinib—CAMK2G—bone marrow—ovarian cancer	0.000848	0.00277	CbGeAlD
Ruxolitinib—TAOK3—uterine cervix—ovarian cancer	0.000846	0.00277	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.000841	0.00382	CcSEcCtD
Ruxolitinib—LRRK2—bone marrow—ovarian cancer	0.00084	0.00275	CbGeAlD
Ruxolitinib—MAP3K3—endometrium—ovarian cancer	0.000839	0.00275	CbGeAlD
Ruxolitinib—ROCK1—testis—ovarian cancer	0.000834	0.00273	CbGeAlD
Ruxolitinib—MARK2—lymph node—ovarian cancer	0.00083	0.00272	CbGeAlD
Ruxolitinib—Infection—Topotecan—ovarian cancer	0.000824	0.00374	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Docetaxel—ovarian cancer	0.000823	0.00373	CcSEcCtD
Ruxolitinib—CAMK2G—female gonad—ovarian cancer	0.000817	0.00267	CbGeAlD
Ruxolitinib—BMP2K—female gonad—ovarian cancer	0.000817	0.00267	CbGeAlD
Ruxolitinib—MAP3K2—female reproductive system—ovarian cancer	0.000815	0.00267	CbGeAlD
Ruxolitinib—Nervous system disorder—Topotecan—ovarian cancer	0.000813	0.00369	CcSEcCtD
Ruxolitinib—DYRK1A—testis—ovarian cancer	0.000813	0.00266	CbGeAlD
Ruxolitinib—Thrombocytopenia—Topotecan—ovarian cancer	0.000812	0.00368	CcSEcCtD
Ruxolitinib—CAMK2G—vagina—ovarian cancer	0.000812	0.00266	CbGeAlD
Ruxolitinib—BMP2K—vagina—ovarian cancer	0.000812	0.00266	CbGeAlD
Ruxolitinib—BMPR2—testis—ovarian cancer	0.00081	0.00265	CbGeAlD
Ruxolitinib—LRRK2—female gonad—ovarian cancer	0.00081	0.00265	CbGeAlD
Ruxolitinib—JAK2—gonad—ovarian cancer	0.000808	0.00264	CbGeAlD
Ruxolitinib—Infection—Melphalan—ovarian cancer	0.000807	0.00366	CcSEcCtD
Ruxolitinib—TAOK3—decidua—ovarian cancer	0.000806	0.00264	CbGeAlD
Ruxolitinib—Skin disorder—Topotecan—ovarian cancer	0.000806	0.00365	CcSEcCtD
Ruxolitinib—LRRK2—vagina—ovarian cancer	0.000805	0.00263	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.000804	0.00365	CcSEcCtD
Ruxolitinib—Anaemia—Vinorelbine—ovarian cancer	0.000804	0.00364	CcSEcCtD
Ruxolitinib—Fatigue—Chlorambucil—ovarian cancer	0.000803	0.00364	CcSEcCtD
Ruxolitinib—Bone pain—Epirubicin—ovarian cancer	0.000798	0.00362	CcSEcCtD
Ruxolitinib—Pancytopenia—Paclitaxel—ovarian cancer	0.000797	0.00361	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Melphalan—ovarian cancer	0.000795	0.00361	CcSEcCtD
Ruxolitinib—TYK2—female reproductive system—ovarian cancer	0.000793	0.0026	CbGeAlD
Ruxolitinib—Skin disorder—Melphalan—ovarian cancer	0.000789	0.00358	CcSEcCtD
Ruxolitinib—Neutropenia—Paclitaxel—ovarian cancer	0.000785	0.00356	CcSEcCtD
Ruxolitinib—MKNK2—female reproductive system—ovarian cancer	0.000783	0.00256	CbGeAlD
Ruxolitinib—IRAK1—female reproductive system—ovarian cancer	0.000783	0.00256	CbGeAlD
Ruxolitinib—MAP3K3—gonad—ovarian cancer	0.000779	0.00255	CbGeAlD
Ruxolitinib—NUAK2—testis—ovarian cancer	0.000774	0.00253	CbGeAlD
Ruxolitinib—MAP3K2—bone marrow—ovarian cancer	0.00077	0.00252	CbGeAlD
Ruxolitinib—TAOK2—lymph node—ovarian cancer	0.000768	0.00252	CbGeAlD
Ruxolitinib—TAOK3—endometrium—ovarian cancer	0.000765	0.00251	CbGeAlD
Ruxolitinib—Weight increased—Paclitaxel—ovarian cancer	0.000764	0.00346	CcSEcCtD
Ruxolitinib—MAP3K7—bone marrow—ovarian cancer	0.000762	0.0025	CbGeAlD
Ruxolitinib—Weight decreased—Paclitaxel—ovarian cancer	0.000759	0.00344	CcSEcCtD
Ruxolitinib—TYK2—bone marrow—ovarian cancer	0.000749	0.00245	CbGeAlD
Ruxolitinib—Infestation—Paclitaxel—ovarian cancer	0.000748	0.00339	CcSEcCtD
Ruxolitinib—Infestation NOS—Paclitaxel—ovarian cancer	0.000748	0.00339	CcSEcCtD
Ruxolitinib—MAP3K2—female gonad—ovarian cancer	0.000742	0.00243	CbGeAlD
Ruxolitinib—MKNK2—bone marrow—ovarian cancer	0.000739	0.00242	CbGeAlD
Ruxolitinib—IRAK1—bone marrow—ovarian cancer	0.000739	0.00242	CbGeAlD
Ruxolitinib—Bone pain—Doxorubicin—ovarian cancer	0.000739	0.00335	CcSEcCtD
Ruxolitinib—Body temperature increased—Chlorambucil—ovarian cancer	0.000737	0.00334	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000735	0.00333	CcSEcCtD
Ruxolitinib—MAP3K7—female gonad—ovarian cancer	0.000735	0.00241	CbGeAlD
Ruxolitinib—MAP3K7—vagina—ovarian cancer	0.00073	0.00239	CbGeAlD
Ruxolitinib—Urinary tract infection—Paclitaxel—ovarian cancer	0.000727	0.0033	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Docetaxel—ovarian cancer	0.000726	0.00329	CcSEcCtD
Ruxolitinib—CAMK2G—testis—ovarian cancer	0.000725	0.00237	CbGeAlD
Ruxolitinib—BMP2K—testis—ovarian cancer	0.000725	0.00237	CbGeAlD
Ruxolitinib—TYK2—female gonad—ovarian cancer	0.000722	0.00236	CbGeAlD
Ruxolitinib—JAK2—female reproductive system—ovarian cancer	0.000722	0.00236	CbGeAlD
Ruxolitinib—LRRK2—testis—ovarian cancer	0.000718	0.00235	CbGeAlD
Ruxolitinib—TYK2—vagina—ovarian cancer	0.000717	0.00235	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000716	0.00325	CcSEcCtD
Ruxolitinib—Fatigue—Topotecan—ovarian cancer	0.000715	0.00324	CcSEcCtD
Ruxolitinib—Haematuria—Paclitaxel—ovarian cancer	0.000714	0.00324	CcSEcCtD
Ruxolitinib—MKNK2—female gonad—ovarian cancer	0.000712	0.00233	CbGeAlD
Ruxolitinib—IRAK1—female gonad—ovarian cancer	0.000712	0.00233	CbGeAlD
Ruxolitinib—MKNK2—vagina—ovarian cancer	0.000708	0.00232	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Paclitaxel—ovarian cancer	0.000708	0.00321	CcSEcCtD
Ruxolitinib—JAK3—lymph node—ovarian cancer	0.000706	0.00231	CbGeAlD
Ruxolitinib—Epistaxis—Paclitaxel—ovarian cancer	0.000706	0.0032	CcSEcCtD
Ruxolitinib—TAOK3—uterus—ovarian cancer	0.000705	0.00231	CbGeAlD
Ruxolitinib—Infection—Vinorelbine—ovarian cancer	0.000705	0.0032	CcSEcCtD
Ruxolitinib—JAK1—lymph node—ovarian cancer	0.000702	0.0023	CbGeAlD
Ruxolitinib—DCLK1—lymph node—ovarian cancer	0.000702	0.0023	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000701	0.00318	CcSEcCtD
Ruxolitinib—Fatigue—Melphalan—ovarian cancer	0.0007	0.00318	CcSEcCtD
Ruxolitinib—PLK4—lymph node—ovarian cancer	0.000697	0.00228	CbGeAlD
Ruxolitinib—Nervous system disorder—Vinorelbine—ovarian cancer	0.000696	0.00316	CcSEcCtD
Ruxolitinib—MAP3K3—female reproductive system—ovarian cancer	0.000695	0.00228	CbGeAlD
Ruxolitinib—Thrombocytopenia—Vinorelbine—ovarian cancer	0.000695	0.00315	CcSEcCtD
Ruxolitinib—Skin disorder—Vinorelbine—ovarian cancer	0.000689	0.00313	CcSEcCtD
Ruxolitinib—CAMK1D—lymph node—ovarian cancer	0.000685	0.00224	CbGeAlD
Ruxolitinib—JAK2—bone marrow—ovarian cancer	0.000681	0.00223	CbGeAlD
Ruxolitinib—PHKG2—lymph node—ovarian cancer	0.000681	0.00223	CbGeAlD
Ruxolitinib—Pancytopenia—Docetaxel—ovarian cancer	0.000676	0.00306	CcSEcCtD
Ruxolitinib—Haemoglobin—Paclitaxel—ovarian cancer	0.000675	0.00306	CcSEcCtD
Ruxolitinib—Haemorrhage—Paclitaxel—ovarian cancer	0.000672	0.00305	CcSEcCtD
Ruxolitinib—DAPK2—lymph node—ovarian cancer	0.000669	0.00219	CbGeAlD
Ruxolitinib—Asthenia—Chlorambucil—ovarian cancer	0.000669	0.00303	CcSEcCtD
Ruxolitinib—Neutropenia—Docetaxel—ovarian cancer	0.000665	0.00302	CcSEcCtD
Ruxolitinib—Pruritus—Chlorambucil—ovarian cancer	0.000659	0.00299	CcSEcCtD
Ruxolitinib—STK16—lymph node—ovarian cancer	0.000658	0.00216	CbGeAlD
Ruxolitinib—MAP3K2—testis—ovarian cancer	0.000658	0.00215	CbGeAlD
Ruxolitinib—JAK2—female gonad—ovarian cancer	0.000657	0.00215	CbGeAlD
Ruxolitinib—MAP3K3—bone marrow—ovarian cancer	0.000657	0.00215	CbGeAlD
Ruxolitinib—Body temperature increased—Topotecan—ovarian cancer	0.000656	0.00297	CcSEcCtD
Ruxolitinib—HIPK2—lymph node—ovarian cancer	0.000655	0.00214	CbGeAlD
Ruxolitinib—JAK2—vagina—ovarian cancer	0.000653	0.00214	CbGeAlD
Ruxolitinib—MAP3K7—testis—ovarian cancer	0.000652	0.00213	CbGeAlD
Ruxolitinib—Weight increased—Docetaxel—ovarian cancer	0.000647	0.00294	CcSEcCtD
Ruxolitinib—Weight decreased—Docetaxel—ovarian cancer	0.000644	0.00292	CcSEcCtD
Ruxolitinib—TYK2—testis—ovarian cancer	0.00064	0.0021	CbGeAlD
Ruxolitinib—Infestation NOS—Docetaxel—ovarian cancer	0.000634	0.00288	CcSEcCtD
Ruxolitinib—Infestation—Docetaxel—ovarian cancer	0.000634	0.00288	CcSEcCtD
Ruxolitinib—TAOK3—female reproductive system—ovarian cancer	0.000634	0.00208	CbGeAlD
Ruxolitinib—MAP3K3—female gonad—ovarian cancer	0.000633	0.00207	CbGeAlD
Ruxolitinib—MKNK2—testis—ovarian cancer	0.000632	0.00207	CbGeAlD
Ruxolitinib—IRAK1—testis—ovarian cancer	0.000632	0.00207	CbGeAlD
Ruxolitinib—DAPK3—lymph node—ovarian cancer	0.000629	0.00206	CbGeAlD
Ruxolitinib—MAP3K3—vagina—ovarian cancer	0.000629	0.00206	CbGeAlD
Ruxolitinib—CLK2—lymph node—ovarian cancer	0.000623	0.00204	CbGeAlD
Ruxolitinib—RET—testis—ovarian cancer	0.000616	0.00202	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000613	0.00278	CcSEcCtD
Ruxolitinib—Fatigue—Vinorelbine—ovarian cancer	0.000612	0.00277	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Docetaxel—ovarian cancer	0.0006	0.00272	CcSEcCtD
Ruxolitinib—TAOK3—bone marrow—ovarian cancer	0.000599	0.00196	CbGeAlD
Ruxolitinib—Epistaxis—Docetaxel—ovarian cancer	0.000598	0.00271	CcSEcCtD
Ruxolitinib—Asthenia—Topotecan—ovarian cancer	0.000595	0.0027	CcSEcCtD
Ruxolitinib—DYRK1A—lymph node—ovarian cancer	0.000589	0.00193	CbGeAlD
Ruxolitinib—BMPR2—lymph node—ovarian cancer	0.000587	0.00192	CbGeAlD
Ruxolitinib—Pruritus—Topotecan—ovarian cancer	0.000587	0.00266	CcSEcCtD
Ruxolitinib—Malnutrition—Paclitaxel—ovarian cancer	0.000585	0.00265	CcSEcCtD
Ruxolitinib—Asthenia—Melphalan—ovarian cancer	0.000583	0.00264	CcSEcCtD
Ruxolitinib—JAK2—testis—ovarian cancer	0.000582	0.00191	CbGeAlD
Ruxolitinib—TAOK3—female gonad—ovarian cancer	0.000577	0.00189	CbGeAlD
Ruxolitinib—Flatulence—Paclitaxel—ovarian cancer	0.000576	0.00261	CcSEcCtD
Ruxolitinib—Pruritus—Melphalan—ovarian cancer	0.000575	0.00261	CcSEcCtD
Ruxolitinib—TAOK3—vagina—ovarian cancer	0.000573	0.00188	CbGeAlD
Ruxolitinib—Haemoglobin—Docetaxel—ovarian cancer	0.000572	0.0026	CcSEcCtD
Ruxolitinib—Haemorrhage—Docetaxel—ovarian cancer	0.000569	0.00258	CcSEcCtD
Ruxolitinib—MAP3K3—testis—ovarian cancer	0.000561	0.00184	CbGeAlD
Ruxolitinib—Body temperature increased—Vinorelbine—ovarian cancer	0.000561	0.00254	CcSEcCtD
Ruxolitinib—NUAK2—lymph node—ovarian cancer	0.000561	0.00184	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Epirubicin—ovarian cancer	0.000555	0.00252	CcSEcCtD
Ruxolitinib—Dizziness—Topotecan—ovarian cancer	0.000549	0.00249	CcSEcCtD
Ruxolitinib—Anaemia—Paclitaxel—ovarian cancer	0.000541	0.00245	CcSEcCtD
Ruxolitinib—CAMK2G—lymph node—ovarian cancer	0.000525	0.00172	CbGeAlD
Ruxolitinib—BMP2K—lymph node—ovarian cancer	0.000525	0.00172	CbGeAlD
Ruxolitinib—LRRK2—lymph node—ovarian cancer	0.000521	0.0017	CbGeAlD
Ruxolitinib—Headache—Topotecan—ovarian cancer	0.00052	0.00236	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Doxorubicin—ovarian cancer	0.000514	0.00233	CcSEcCtD
Ruxolitinib—TAOK3—testis—ovarian cancer	0.000512	0.00168	CbGeAlD
Ruxolitinib—Asthenia—Vinorelbine—ovarian cancer	0.000509	0.00231	CcSEcCtD
Ruxolitinib—Pruritus—Vinorelbine—ovarian cancer	0.000502	0.00228	CcSEcCtD
Ruxolitinib—Malnutrition—Docetaxel—ovarian cancer	0.000496	0.00225	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000494	0.00224	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.00049	0.00222	CcSEcCtD
Ruxolitinib—MAP3K2—lymph node—ovarian cancer	0.000477	0.00156	CbGeAlD
Ruxolitinib—Infection—Paclitaxel—ovarian cancer	0.000474	0.00215	CcSEcCtD
Ruxolitinib—MAP3K7—lymph node—ovarian cancer	0.000472	0.00155	CbGeAlD
Ruxolitinib—Dizziness—Vinorelbine—ovarian cancer	0.000469	0.00213	CcSEcCtD
Ruxolitinib—Nervous system disorder—Paclitaxel—ovarian cancer	0.000468	0.00212	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000467	0.00212	CcSEcCtD
Ruxolitinib—TYK2—lymph node—ovarian cancer	0.000464	0.00152	CbGeAlD
Ruxolitinib—Skin disorder—Paclitaxel—ovarian cancer	0.000464	0.0021	CcSEcCtD
Ruxolitinib—Anaemia—Docetaxel—ovarian cancer	0.000458	0.00208	CcSEcCtD
Ruxolitinib—IRAK1—lymph node—ovarian cancer	0.000458	0.0015	CbGeAlD
Ruxolitinib—MKNK2—lymph node—ovarian cancer	0.000458	0.0015	CbGeAlD
Ruxolitinib—Pancytopenia—Epirubicin—ovarian cancer	0.000456	0.00207	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000453	0.00205	CcSEcCtD
Ruxolitinib—Neutropenia—Epirubicin—ovarian cancer	0.000449	0.00203	CcSEcCtD
Ruxolitinib—RET—lymph node—ovarian cancer	0.000447	0.00146	CbGeAlD
Ruxolitinib—Headache—Vinorelbine—ovarian cancer	0.000445	0.00202	CcSEcCtD
Ruxolitinib—Weight increased—Epirubicin—ovarian cancer	0.000437	0.00198	CcSEcCtD
Ruxolitinib—Weight decreased—Epirubicin—ovarian cancer	0.000434	0.00197	CcSEcCtD
Ruxolitinib—Infestation NOS—Epirubicin—ovarian cancer	0.000428	0.00194	CcSEcCtD
Ruxolitinib—Infestation—Epirubicin—ovarian cancer	0.000428	0.00194	CcSEcCtD
Ruxolitinib—JAK2—lymph node—ovarian cancer	0.000422	0.00138	CbGeAlD
Ruxolitinib—Pancytopenia—Doxorubicin—ovarian cancer	0.000422	0.00191	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000419	0.0019	CcSEcCtD
Ruxolitinib—Urinary tract infection—Epirubicin—ovarian cancer	0.000416	0.00189	CcSEcCtD
Ruxolitinib—Neutropenia—Doxorubicin—ovarian cancer	0.000415	0.00188	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000412	0.00187	CcSEcCtD
Ruxolitinib—Fatigue—Paclitaxel—ovarian cancer	0.000412	0.00187	CcSEcCtD
Ruxolitinib—Haematuria—Epirubicin—ovarian cancer	0.000408	0.00185	CcSEcCtD
Ruxolitinib—MAP3K3—lymph node—ovarian cancer	0.000407	0.00133	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000405	0.00183	CcSEcCtD
Ruxolitinib—Weight increased—Doxorubicin—ovarian cancer	0.000404	0.00183	CcSEcCtD
Ruxolitinib—Epistaxis—Epirubicin—ovarian cancer	0.000404	0.00183	CcSEcCtD
Ruxolitinib—Infection—Docetaxel—ovarian cancer	0.000402	0.00182	CcSEcCtD
Ruxolitinib—Weight decreased—Doxorubicin—ovarian cancer	0.000402	0.00182	CcSEcCtD
Ruxolitinib—Nervous system disorder—Docetaxel—ovarian cancer	0.000397	0.0018	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Docetaxel—ovarian cancer	0.000396	0.0018	CcSEcCtD
Ruxolitinib—Infestation—Doxorubicin—ovarian cancer	0.000396	0.0018	CcSEcCtD
Ruxolitinib—Infestation NOS—Doxorubicin—ovarian cancer	0.000396	0.0018	CcSEcCtD
Ruxolitinib—Skin disorder—Docetaxel—ovarian cancer	0.000393	0.00178	CcSEcCtD
Ruxolitinib—Haemoglobin—Epirubicin—ovarian cancer	0.000386	0.00175	CcSEcCtD
Ruxolitinib—Urinary tract infection—Doxorubicin—ovarian cancer	0.000385	0.00175	CcSEcCtD
Ruxolitinib—Haemorrhage—Epirubicin—ovarian cancer	0.000384	0.00174	CcSEcCtD
Ruxolitinib—Haematuria—Doxorubicin—ovarian cancer	0.000377	0.00171	CcSEcCtD
Ruxolitinib—Body temperature increased—Paclitaxel—ovarian cancer	0.000377	0.00171	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000374	0.0017	CcSEcCtD
Ruxolitinib—Epistaxis—Doxorubicin—ovarian cancer	0.000373	0.00169	CcSEcCtD
Ruxolitinib—TAOK3—lymph node—ovarian cancer	0.000371	0.00121	CbGeAlD
Ruxolitinib—Haemoglobin—Doxorubicin—ovarian cancer	0.000357	0.00162	CcSEcCtD
Ruxolitinib—Haemorrhage—Doxorubicin—ovarian cancer	0.000355	0.00161	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000349	0.00158	CcSEcCtD
Ruxolitinib—Fatigue—Docetaxel—ovarian cancer	0.000349	0.00158	CcSEcCtD
Ruxolitinib—Asthenia—Paclitaxel—ovarian cancer	0.000342	0.00155	CcSEcCtD
Ruxolitinib—Pruritus—Paclitaxel—ovarian cancer	0.000338	0.00153	CcSEcCtD
Ruxolitinib—Malnutrition—Epirubicin—ovarian cancer	0.000334	0.00152	CcSEcCtD
Ruxolitinib—Flatulence—Epirubicin—ovarian cancer	0.000329	0.00149	CcSEcCtD
Ruxolitinib—Body temperature increased—Docetaxel—ovarian cancer	0.00032	0.00145	CcSEcCtD
Ruxolitinib—DYRK1A—Idarubicin—Epirubicin—ovarian cancer	0.000318	0.0301	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Epirubicin—ovarian cancer	0.000318	0.0301	CbGdCrCtD
Ruxolitinib—DYRK1A—Doxorubicin—Epirubicin—ovarian cancer	0.000318	0.0301	CbGdCrCtD
Ruxolitinib—Dizziness—Paclitaxel—ovarian cancer	0.000316	0.00143	CcSEcCtD
Ruxolitinib—Malnutrition—Doxorubicin—ovarian cancer	0.000309	0.0014	CcSEcCtD
Ruxolitinib—Anaemia—Epirubicin—ovarian cancer	0.000309	0.0014	CcSEcCtD
Ruxolitinib—Flatulence—Doxorubicin—ovarian cancer	0.000305	0.00138	CcSEcCtD
Ruxolitinib—Headache—Paclitaxel—ovarian cancer	0.000299	0.00136	CcSEcCtD
Ruxolitinib—DYRK1A—Idarubicin—Doxorubicin—ovarian cancer	0.000294	0.0279	CbGdCrCtD
Ruxolitinib—DYRK1A—Epirubicin—Doxorubicin—ovarian cancer	0.000294	0.0279	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Doxorubicin—ovarian cancer	0.000294	0.0279	CbGdCrCtD
Ruxolitinib—Asthenia—Docetaxel—ovarian cancer	0.00029	0.00132	CcSEcCtD
Ruxolitinib—Pruritus—Docetaxel—ovarian cancer	0.000286	0.0013	CcSEcCtD
Ruxolitinib—Anaemia—Doxorubicin—ovarian cancer	0.000286	0.0013	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000283	0.00128	CcSEcCtD
Ruxolitinib—Infection—Epirubicin—ovarian cancer	0.000271	0.00123	CcSEcCtD
Ruxolitinib—Nervous system disorder—Epirubicin—ovarian cancer	0.000268	0.00121	CcSEcCtD
Ruxolitinib—Dizziness—Docetaxel—ovarian cancer	0.000268	0.00121	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Epirubicin—ovarian cancer	0.000267	0.00121	CcSEcCtD
Ruxolitinib—Skin disorder—Epirubicin—ovarian cancer	0.000265	0.0012	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000262	0.00119	CcSEcCtD
Ruxolitinib—Headache—Docetaxel—ovarian cancer	0.000253	0.00115	CcSEcCtD
Ruxolitinib—Infection—Doxorubicin—ovarian cancer	0.000251	0.00114	CcSEcCtD
Ruxolitinib—Nervous system disorder—Doxorubicin—ovarian cancer	0.000248	0.00112	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000247	0.00112	CcSEcCtD
Ruxolitinib—Skin disorder—Doxorubicin—ovarian cancer	0.000245	0.00111	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000236	0.00107	CcSEcCtD
Ruxolitinib—Fatigue—Epirubicin—ovarian cancer	0.000235	0.00107	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000218	0.000988	CcSEcCtD
Ruxolitinib—Fatigue—Doxorubicin—ovarian cancer	0.000218	0.000987	CcSEcCtD
Ruxolitinib—PLK1—Daunorubicin—Epirubicin—ovarian cancer	0.000217	0.0206	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Epirubicin—ovarian cancer	0.000217	0.0206	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Epirubicin—ovarian cancer	0.000217	0.0206	CbGdCrCtD
Ruxolitinib—PLK1—Doxorubicin—Epirubicin—ovarian cancer	0.000217	0.0206	CbGdCrCtD
Ruxolitinib—PLK4—Doxorubicin—Epirubicin—ovarian cancer	0.000217	0.0206	CbGdCrCtD
Ruxolitinib—Body temperature increased—Epirubicin—ovarian cancer	0.000216	0.000978	CcSEcCtD
Ruxolitinib—PLK1—Daunorubicin—Doxorubicin—ovarian cancer	0.000201	0.019	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Doxorubicin—ovarian cancer	0.000201	0.019	CbGdCrCtD
Ruxolitinib—PLK4—Epirubicin—Doxorubicin—ovarian cancer	0.000201	0.019	CbGdCrCtD
Ruxolitinib—PLK1—Epirubicin—Doxorubicin—ovarian cancer	0.000201	0.019	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Doxorubicin—ovarian cancer	0.000201	0.019	CbGdCrCtD
Ruxolitinib—Body temperature increased—Doxorubicin—ovarian cancer	0.0002	0.000905	CcSEcCtD
Ruxolitinib—Asthenia—Epirubicin—ovarian cancer	0.000196	0.000888	CcSEcCtD
Ruxolitinib—Pruritus—Epirubicin—ovarian cancer	0.000193	0.000875	CcSEcCtD
Ruxolitinib—CYP3A4—female reproductive system—ovarian cancer	0.000193	0.000631	CbGeAlD
Ruxolitinib—Asthenia—Doxorubicin—ovarian cancer	0.000181	0.000821	CcSEcCtD
Ruxolitinib—Dizziness—Epirubicin—ovarian cancer	0.00018	0.000818	CcSEcCtD
Ruxolitinib—Pruritus—Doxorubicin—ovarian cancer	0.000179	0.00081	CcSEcCtD
Ruxolitinib—Headache—Epirubicin—ovarian cancer	0.000171	0.000775	CcSEcCtD
Ruxolitinib—Dizziness—Doxorubicin—ovarian cancer	0.000167	0.000757	CcSEcCtD
Ruxolitinib—Headache—Doxorubicin—ovarian cancer	0.000158	0.000717	CcSEcCtD
Ruxolitinib—JAK2—Innate Immune System—HRAS—ovarian cancer	4.88e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—AKT1—ovarian cancer	4.88e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL6—ovarian cancer	4.86e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—BRIP1—ovarian cancer	4.86e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPP1CC—ovarian cancer	4.86e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MYC—ovarian cancer	4.86e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—KRAS—ovarian cancer	4.83e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—AKT1—ovarian cancer	4.83e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MAPK1—ovarian cancer	4.81e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EGFR—ovarian cancer	4.81e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—AKT1—ovarian cancer	4.78e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CD—ovarian cancer	4.78e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MAPK3—ovarian cancer	4.76e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MAPK1—ovarian cancer	4.75e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EGFR—ovarian cancer	4.75e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—STAT3—ovarian cancer	4.74e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NRAS—ovarian cancer	4.73e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—ovarian cancer	4.73e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDKN1B—ovarian cancer	4.73e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ERBB2—ovarian cancer	4.71e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—HRAS—ovarian cancer	4.69e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MAPK1—ovarian cancer	4.67e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IL6—ovarian cancer	4.67e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EGFR—ovarian cancer	4.67e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CAV1—ovarian cancer	4.67e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CB—ovarian cancer	4.65e-06	1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MTOR—ovarian cancer	4.65e-06	1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL2—ovarian cancer	4.63e-06	9.98e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—ovarian cancer	4.54e-06	9.8e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KRAS—ovarian cancer	4.54e-06	9.8e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MAPK3—ovarian cancer	4.53e-06	9.78e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MAPK1—ovarian cancer	4.53e-06	9.77e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EGFR—ovarian cancer	4.53e-06	9.77e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HRAS—ovarian cancer	4.52e-06	9.76e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—STAT3—ovarian cancer	4.5e-06	9.71e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ESR1—ovarian cancer	4.5e-06	9.7e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KRAS—ovarian cancer	4.49e-06	9.69e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NRAS—ovarian cancer	4.49e-06	9.68e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6—ovarian cancer	4.49e-06	9.68e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ERBB2—ovarian cancer	4.49e-06	9.68e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—AKT1—ovarian cancer	4.48e-06	9.68e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—ovarian cancer	4.47e-06	9.64e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CTNNB1—ovarian cancer	4.47e-06	9.64e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PIK3CA—ovarian cancer	4.44e-06	9.57e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MTOR—ovarian cancer	4.43e-06	9.55e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CB—ovarian cancer	4.43e-06	9.55e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—STAT3—ovarian cancer	4.43e-06	9.55e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6ST—ovarian cancer	4.42e-06	9.55e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NRAS—ovarian cancer	4.41e-06	9.52e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KRAS—ovarian cancer	4.41e-06	9.52e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MYC—ovarian cancer	4.41e-06	9.51e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CDKN1B—ovarian cancer	4.37e-06	9.42e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ERBB2—ovarian cancer	4.36e-06	9.4e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PTEN—ovarian cancer	4.35e-06	9.39e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—ovarian cancer	4.33e-06	9.34e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MAPK1—ovarian cancer	4.31e-06	9.3e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EGFR—ovarian cancer	4.31e-06	9.3e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—AKT1—ovarian cancer	4.31e-06	9.29e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK3—ovarian cancer	4.3e-06	9.27e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MTOR—ovarian cancer	4.3e-06	9.27e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CB—ovarian cancer	4.3e-06	9.27e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KRAS—ovarian cancer	4.28e-06	9.23e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CXCL8—ovarian cancer	4.25e-06	9.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CG—ovarian cancer	4.25e-06	9.17e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APC—ovarian cancer	4.25e-06	9.17e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—NRAS—ovarian cancer	4.25e-06	9.17e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK3—ovarian cancer	4.23e-06	9.12e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ERBB2—ovarian cancer	4.22e-06	9.11e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MYC—ovarian cancer	4.18e-06	9.02e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PIK3CA—ovarian cancer	4.17e-06	9.01e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MTOR—ovarian cancer	4.17e-06	8.99e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CB—ovarian cancer	4.17e-06	8.99e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDKN1B—ovarian cancer	4.15e-06	8.96e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT1—ovarian cancer	4.14e-06	8.93e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCL8—ovarian cancer	4.13e-06	8.91e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PIK3CA—ovarian cancer	4.13e-06	8.9e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CTNNB1—ovarian cancer	4.12e-06	8.9e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MYC—ovarian cancer	4.11e-06	8.87e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—ovarian cancer	4.1e-06	8.85e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK1—ovarian cancer	4.09e-06	8.82e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—ovarian cancer	4.09e-06	8.82e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KRAS—ovarian cancer	4.07e-06	8.79e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CASP3—ovarian cancer	4.07e-06	8.79e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—MAPK3—ovarian cancer	4.07e-06	8.78e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL2—ovarian cancer	4.07e-06	8.77e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PIK3CA—ovarian cancer	4.05e-06	8.74e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDKN1B—ovarian cancer	4.03e-06	8.7e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK1—ovarian cancer	4.02e-06	8.68e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—ovarian cancer	4.02e-06	8.68e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTEN—ovarian cancer	4.02e-06	8.67e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCL8—ovarian cancer	4.01e-06	8.64e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT1—ovarian cancer	3.99e-06	8.62e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—ovarian cancer	3.99e-06	8.61e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCND1—ovarian cancer	3.96e-06	8.55e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CASP3—ovarian cancer	3.95e-06	8.53e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL2—ovarian cancer	3.95e-06	8.52e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PIK3CA—ovarian cancer	3.93e-06	8.48e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—ovarian cancer	3.93e-06	8.47e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CTNNB1—ovarian cancer	3.92e-06	8.47e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDKN1B—ovarian cancer	3.91e-06	8.44e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—STAT3—ovarian cancer	3.89e-06	8.4e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NRAS—ovarian cancer	3.88e-06	8.38e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—MAPK1—ovarian cancer	3.87e-06	8.36e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—ovarian cancer	3.87e-06	8.36e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KRAS—ovarian cancer	3.86e-06	8.33e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—ovarian cancer	3.86e-06	8.33e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—ovarian cancer	3.85e-06	8.3e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCND1—ovarian cancer	3.85e-06	8.3e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CASP3—ovarian cancer	3.83e-06	8.27e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL2—ovarian cancer	3.83e-06	8.26e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PTEN—ovarian cancer	3.83e-06	8.25e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—ovarian cancer	3.82e-06	8.24e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CTNNB1—ovarian cancer	3.81e-06	8.22e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KRAS—ovarian cancer	3.8e-06	8.2e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—ovarian cancer	3.75e-06	8.09e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PIK3CA—ovarian cancer	3.74e-06	8.07e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CD—ovarian cancer	3.74e-06	8.06e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—ovarian cancer	3.74e-06	8.06e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCND1—ovarian cancer	3.73e-06	8.05e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK3—ovarian cancer	3.72e-06	8.03e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PTEN—ovarian cancer	3.71e-06	8.01e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—PIK3CA—ovarian cancer	3.7e-06	7.99e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—ovarian cancer	3.7e-06	7.98e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CTNNB1—ovarian cancer	3.7e-06	7.97e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—KRAS—ovarian cancer	3.66e-06	7.89e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—ovarian cancer	3.65e-06	7.88e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—ovarian cancer	3.64e-06	7.85e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—ovarian cancer	3.62e-06	7.82e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT1—ovarian cancer	3.62e-06	7.82e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTEN—ovarian cancer	3.6e-06	7.77e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—STAT3—ovarian cancer	3.59e-06	7.76e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—ovarian cancer	3.59e-06	7.74e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NRAS—ovarian cancer	3.59e-06	7.74e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PIK3CA—ovarian cancer	3.55e-06	7.66e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK1—ovarian cancer	3.54e-06	7.64e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—ovarian cancer	3.54e-06	7.63e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PIK3CA—ovarian cancer	3.49e-06	7.53e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—ovarian cancer	3.48e-06	7.51e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—ovarian cancer	3.46e-06	7.47e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—ovarian cancer	3.46e-06	7.46e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MAPK3—ovarian cancer	3.43e-06	7.41e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—ovarian cancer	3.43e-06	7.41e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—STAT3—ovarian cancer	3.42e-06	7.38e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NRAS—ovarian cancer	3.41e-06	7.36e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT1—ovarian cancer	3.41e-06	7.36e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—ovarian cancer	3.38e-06	7.29e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT1—ovarian cancer	3.37e-06	7.27e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PIK3CA—ovarian cancer	3.36e-06	7.25e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—ovarian cancer	3.35e-06	7.24e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KRAS—ovarian cancer	3.34e-06	7.21e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MYC—ovarian cancer	3.34e-06	7.21e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—STAT3—ovarian cancer	3.32e-06	7.17e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NRAS—ovarian cancer	3.31e-06	7.15e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—ovarian cancer	3.31e-06	7.15e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT1—ovarian cancer	3.31e-06	7.14e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ERBB2—ovarian cancer	3.3e-06	7.12e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—ovarian cancer	3.28e-06	7.08e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK3—ovarian cancer	3.27e-06	7.05e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MAPK1—ovarian cancer	3.27e-06	7.05e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—ovarian cancer	3.27e-06	7.05e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—YAP1—ovarian cancer	3.26e-06	7.03e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CB—ovarian cancer	3.26e-06	7.03e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MTOR—ovarian cancer	3.26e-06	7.03e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—ovarian cancer	3.25e-06	7.02e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—ovarian cancer	3.23e-06	6.97e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—STAT3—ovarian cancer	3.22e-06	6.95e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NRAS—ovarian cancer	3.21e-06	6.93e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT1—ovarian cancer	3.21e-06	6.93e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MYC—ovarian cancer	3.18e-06	6.86e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK3—ovarian cancer	3.17e-06	6.85e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—ovarian cancer	3.14e-06	6.78e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCL8—ovarian cancer	3.13e-06	6.75e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK1—ovarian cancer	3.11e-06	6.71e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—ovarian cancer	3.11e-06	6.71e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—ovarian cancer	3.11e-06	6.71e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—ovarian cancer	3.09e-06	6.67e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MYC—ovarian cancer	3.09e-06	6.66e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KRAS—ovarian cancer	3.09e-06	6.66e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK3—ovarian cancer	3.08e-06	6.64e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CA—ovarian cancer	3.07e-06	6.63e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN1B—ovarian cancer	3.06e-06	6.6e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT1—ovarian cancer	3.06e-06	6.59e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT1—ovarian cancer	3.02e-06	6.52e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK1—ovarian cancer	3.02e-06	6.51e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—ovarian cancer	3.02e-06	6.51e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CASP3—ovarian cancer	3e-06	6.46e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MYC—ovarian cancer	2.99e-06	6.46e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL2—ovarian cancer	2.99e-06	6.45e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—ovarian cancer	2.98e-06	6.42e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KRAS—ovarian cancer	2.94e-06	6.34e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK1—ovarian cancer	2.93e-06	6.32e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—ovarian cancer	2.93e-06	6.32e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCND1—ovarian cancer	2.92e-06	6.29e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT1—ovarian cancer	2.9e-06	6.26e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CTNNB1—ovarian cancer	2.89e-06	6.23e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KRAS—ovarian cancer	2.85e-06	6.15e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT1—ovarian cancer	2.85e-06	6.15e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—ovarian cancer	2.84e-06	6.13e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CA—ovarian cancer	2.84e-06	6.12e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—ovarian cancer	2.83e-06	6.11e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTEN—ovarian cancer	2.81e-06	6.07e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KRAS—ovarian cancer	2.77e-06	5.97e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT1—ovarian cancer	2.75e-06	5.92e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—ovarian cancer	2.72e-06	5.87e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CA—ovarian cancer	2.7e-06	5.82e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—FASN—ovarian cancer	2.66e-06	5.73e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—ovarian cancer	2.62e-06	5.66e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CA—ovarian cancer	2.62e-06	5.65e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC5A5—ovarian cancer	2.61e-06	5.64e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—ovarian cancer	2.61e-06	5.63e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—ovarian cancer	2.54e-06	5.49e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CA—ovarian cancer	2.54e-06	5.48e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—ovarian cancer	2.53e-06	5.47e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC2A1—ovarian cancer	2.52e-06	5.45e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STAT3—ovarian cancer	2.52e-06	5.43e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NRAS—ovarian cancer	2.51e-06	5.42e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—ovarian cancer	2.51e-06	5.42e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT1—ovarian cancer	2.51e-06	5.41e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—ovarian cancer	2.5e-06	5.39e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—ovarian cancer	2.46e-06	5.3e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—ovarian cancer	2.42e-06	5.23e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP1B1—ovarian cancer	2.42e-06	5.22e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK3—ovarian cancer	2.4e-06	5.19e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—ovarian cancer	2.39e-06	5.16e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—ovarian cancer	2.35e-06	5.07e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MYC—ovarian cancer	2.34e-06	5.05e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—ovarian cancer	2.32e-06	5.01e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT1—ovarian cancer	2.32e-06	5e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK1—ovarian cancer	2.29e-06	4.94e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—ovarian cancer	2.29e-06	4.94e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—ovarian cancer	2.25e-06	4.86e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT1—ovarian cancer	2.2e-06	4.76e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KRAS—ovarian cancer	2.16e-06	4.66e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	2.15e-06	4.63e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT1—ovarian cancer	2.14e-06	4.62e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT1—ovarian cancer	2.08e-06	4.48e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.99e-06	4.3e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CA—ovarian cancer	1.99e-06	4.28e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TYMS—ovarian cancer	1.96e-06	4.22e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—ovarian cancer	1.92e-06	4.14e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—ovarian cancer	1.84e-06	3.96e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—ovarian cancer	1.76e-06	3.79e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT1—ovarian cancer	1.62e-06	3.5e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CAV1—ovarian cancer	1.58e-06	3.4e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.44e-06	3.1e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.26e-06	2.73e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.1e-06	2.38e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTEN—ovarian cancer	9.51e-07	2.05e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CA—ovarian cancer	6.71e-07	1.45e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKT1—ovarian cancer	5.48e-07	1.18e-06	CbGpPWpGaD
